Pharos IBio Co Ltd
388870
Company Profile
Business description
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.
Contact
427beon-gil, Dongan-gu
1407 and 1408, 38, Heungan-daero, Seongji Star With
Gyeonggi-do, Gwanyang-dong
Anyang-si
KORT: +82 313456170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
33
Stocks News & Analysis
stocks
Overvalued ASX share as market underestimates downside risks
Growth outlook solid, but upside more than priced in.
stocks
New production imminent for undervalued ASX gas play
LNG project receives first commissioning gas.
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,322.30 | 38.50 | 0.41% |
CAC 40 | 8,174.20 | 14.39 | -0.18% |
DAX 40 | 23,830.99 | 441.20 | -1.82% |
Dow JONES (US) | 46,190.61 | 238.37 | 0.52% |
FTSE 100 | 9,354.57 | 81.52 | -0.86% |
HKSE | 25,854.98 | 607.88 | 2.41% |
NASDAQ | 22,679.97 | 117.44 | 0.52% |
Nikkei 225 | 48,899.56 | 1,317.41 | 2.77% |
NZX 50 Index | 13,344.96 | 55.75 | 0.42% |
S&P 500 | 6,664.01 | 34.94 | 0.53% |
S&P/ASX 200 | 9,030.10 | 41.90 | 0.47% |
SSE Composite Index | 3,866.09 | 26.34 | 0.69% |